JP6265998B2 - オリゴマー含有ベンズアミド系化合物 - Google Patents

オリゴマー含有ベンズアミド系化合物 Download PDF

Info

Publication number
JP6265998B2
JP6265998B2 JP2015532149A JP2015532149A JP6265998B2 JP 6265998 B2 JP6265998 B2 JP 6265998B2 JP 2015532149 A JP2015532149 A JP 2015532149A JP 2015532149 A JP2015532149 A JP 2015532149A JP 6265998 B2 JP6265998 B2 JP 6265998B2
Authority
JP
Japan
Prior art keywords
compound
metoclopramide
oligomer
mpeg
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015532149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529686A (ja
JP2015529686A5 (enExample
Inventor
リン チェン，
リン チェン，
ジェニファー リグス−ソーサー，
ジェニファー リグス−ソーサー，
ニール ケイ． アナンド，
ニール ケイ． アナンド，
Original Assignee
ネクター セラピューティクス
ネクター セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクター セラピューティクス, ネクター セラピューティクス filed Critical ネクター セラピューティクス
Publication of JP2015529686A publication Critical patent/JP2015529686A/ja
Publication of JP2015529686A5 publication Critical patent/JP2015529686A5/ja
Application granted granted Critical
Publication of JP6265998B2 publication Critical patent/JP6265998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2015532149A 2012-09-17 2013-09-17 オリゴマー含有ベンズアミド系化合物 Active JP6265998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702088P 2012-09-17 2012-09-17
US61/702,088 2012-09-17
PCT/US2013/060179 WO2014043707A1 (en) 2012-09-17 2013-09-17 Oligomer-containing benzamide-based compounds

Publications (3)

Publication Number Publication Date
JP2015529686A JP2015529686A (ja) 2015-10-08
JP2015529686A5 JP2015529686A5 (enExample) 2016-10-27
JP6265998B2 true JP6265998B2 (ja) 2018-01-24

Family

ID=49263466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015532149A Active JP6265998B2 (ja) 2012-09-17 2013-09-17 オリゴマー含有ベンズアミド系化合物

Country Status (4)

Country Link
US (3) US9375486B2 (enExample)
EP (1) EP2895457B1 (enExample)
JP (1) JP6265998B2 (enExample)
WO (1) WO2014043707A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796248B2 (en) * 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
EP2895457B1 (en) 2012-09-17 2020-05-20 Nektar Therapeutics Oligomer-containing benzamide-based compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281394A (enExample) 1961-07-25
FR2313935A1 (fr) 1975-06-10 1977-01-07 Ile De France Nouveaux benzamides substitues, leurs derives et leur procede de preparation
GB1451770A (en) 1972-08-25 1976-10-06 Delmar Chem Processes for making n-dialkyl-aminoalkyl-2-alkoxy-4-amino-5-halo benzamide compounds
JPS49135941A (enExample) * 1973-04-16 1974-12-27
JPS6058224B2 (ja) 1978-07-31 1985-12-19 旭化成株式会社 メトクロプラミドの製造方法
JPS5533416A (en) 1978-08-31 1980-03-08 Sogo Yatsukou Kk Production of hexamethyene bis-dicyandiamide
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5227397A (en) * 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
DK1694363T3 (en) 2003-12-16 2014-03-24 Nektar Therapeutics Monodisperse PEGylated Naloxole Compositions
NZ588373A (en) 2004-05-19 2012-01-12 Emisphere Tech Inc Topical cromolyn formulations
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
WO2007008963A1 (en) * 2005-07-13 2007-01-18 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
EP2121031B1 (en) 2007-03-12 2013-10-16 Nektar Therapeutics Oligomer-antihistamine conjugates
US8389759B2 (en) 2007-03-12 2013-03-05 Nektar Therapeutics Oligomer-anticholinergic agent conjugates
AU2009292631A1 (en) 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
WO2010088340A1 (en) 2009-01-28 2010-08-05 Nektar Therapeutics Oligomer-phenothiazine conjugates
WO2010120387A1 (en) * 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
GB201101209D0 (en) 2011-01-24 2011-03-09 Syngenta Ltd Formulation component
EP2895457B1 (en) 2012-09-17 2020-05-20 Nektar Therapeutics Oligomer-containing benzamide-based compounds

Also Published As

Publication number Publication date
EP2895457A1 (en) 2015-07-22
US9375486B2 (en) 2016-06-28
US9937266B2 (en) 2018-04-10
US20150250894A1 (en) 2015-09-10
US20180185499A1 (en) 2018-07-05
US20160339108A1 (en) 2016-11-24
EP2895457B1 (en) 2020-05-20
WO2014043707A1 (en) 2014-03-20
US10434181B2 (en) 2019-10-08
JP2015529686A (ja) 2015-10-08

Similar Documents

Publication Publication Date Title
JP5827123B2 (ja) 乱用の可能性が低いｐｅｇ化オピオイド
JP5383514B2 (ja) オリゴマー−抗ヒスタミン複合体
JP5704925B2 (ja) オリゴマー−カンナビノイドコンジュゲート
JP5448854B2 (ja) オリゴマー−プロテアーゼ阻害剤複合体
WO2012083153A1 (en) Oligomer-containing apremilast moiety compounds
JP2013151563A (ja) オリゴマー−オピオイドアゴニスト複合体
JP5693967B2 (ja) オリゴマー−ジアリールピペラジンコンジュゲート
US10265411B2 (en) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
JP5877553B2 (ja) オリゴマー−抗コリン剤複合体
JP5792175B2 (ja) オリゴマー−カルシミメティクスコンジュゲートおよび関連化合物
JP6265998B2 (ja) オリゴマー含有ベンズアミド系化合物
US8536213B2 (en) Oligomer-dantrolene conjugates and related compounds
US9421204B2 (en) Oligomer modified diaromatic substituted compounds
KR101799113B1 (ko) 올리고머를 함유하는 치환된 방향족 트리아진 화합물
US9540330B2 (en) Oligomer-containing hydantoin compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160905

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171219

R150 Certificate of patent or registration of utility model

Ref document number: 6265998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250